Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia.
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, Kazmirski SL, Kettle JG, Lamb ML, Matulis SM, Nooka AK, Packer MJ, Peng B, Rawlins PB, Robbins DW, Schuller AG, Su N, Yang W, Ye Q, Zheng X, Secrist JP, Clark EA, Wilson DM, Fawell SE, Hird AW. Tron AE, et al. Among authors: secrist jp. Nat Commun. 2018 Dec 17;9(1):5341. doi: 10.1038/s41467-018-07551-w. Nat Commun. 2018. PMID: 30559424 Free PMC article.
Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl-1 Inhibitor AZD5991.
Goliaei A, Woods HA, Tron AE, Belmonte MA, Secrist JP, Ferguson D, Drew L, Fretland AJ, Aldridge BB, Gibbons FD. Goliaei A, et al. Among authors: secrist jp. CPT Pharmacometrics Syst Pharmacol. 2020 Oct;9(10):561-570. doi: 10.1002/psp4.12552. Epub 2020 Sep 17. CPT Pharmacometrics Syst Pharmacol. 2020. PMID: 32860732 Free PMC article.
AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.
Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P, Macintyre T, Wen S, Lawson D, Burke K, Lubinski T, Tyner JW, Kurtz SE, McWeeney SK, Varnes J, Diebold RB, Gero T, Ioannidis S, Hennessy EJ, McCoull W, Saeh JC, Tabatabai A, Tavana O, Su N, Schuller A, Garnett MJ, Jaaks P, Coker EA, Gregory GP, Newbold A, Johnstone RW, Gangl E, Wild M, Zinda M, Secrist JP, Davies BR, Fawell SE, Gibbons FD. Balachander SB, et al. Among authors: secrist jp. Clin Cancer Res. 2020 Dec 15;26(24):6535-6549. doi: 10.1158/1078-0432.CCR-20-0863. Epub 2020 Sep 28. Clin Cancer Res. 2020. PMID: 32988967
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy.
Patterson CM, Balachander SB, Grant I, Pop-Damkov P, Kelly B, McCoull W, Parker J, Giannis M, Hill KJ, Gibbons FD, Hennessy EJ, Kemmitt P, Harmer AR, Gales S, Purbrick S, Redmond S, Skinner M, Graham L, Secrist JP, Schuller AG, Wen S, Adam A, Reimer C, Cidado J, Wild M, Gangl E, Fawell SE, Saeh J, Davies BR, Owen DJ, Ashford MB. Patterson CM, et al. Among authors: secrist jp. Commun Biol. 2021 Jan 25;4(1):112. doi: 10.1038/s42003-020-01631-8. Commun Biol. 2021. PMID: 33495510 Free PMC article.
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.
Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM. Koch R, et al. Among authors: secrist jp. Blood. 2019 Feb 7;133(6):566-575. doi: 10.1182/blood-2018-07-865527. Epub 2018 Nov 29. Blood. 2019. PMID: 30498064 Free PMC article.
Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, Anthony DA, Banks KM, Haynes NM, Gangatirkar P, Stanley K, Bolden JE, Takeda K, Yagita H, Secrist JP, Smyth MJ, Johnstone RW. Frew AJ, et al. Among authors: secrist jp. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11317-22. doi: 10.1073/pnas.0801868105. Epub 2008 Aug 6. Proc Natl Acad Sci U S A. 2008. PMID: 18685088 Free PMC article.
Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
Newbold A, Matthews GM, Bots M, Cluse LA, Clarke CJ, Banks KM, Cullinane C, Bolden JE, Christiansen AJ, Dickins RA, Miccolo C, Chiocca S, Kral AM, Ozerova ND, Miller TA, Methot JL, Richon VM, Secrist JP, Minucci S, Johnstone RW. Newbold A, et al. Among authors: secrist jp. Mol Cancer Ther. 2013 Dec;12(12):2709-21. doi: 10.1158/1535-7163.MCT-13-0626. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092806
HDAC inhibitors for the treatment of cancer.
Secrist JP, Zhou X, Richon VM. Secrist JP, et al. Curr Opin Investig Drugs. 2003 Dec;4(12):1422-7. Curr Opin Investig Drugs. 2003. PMID: 14763127 Review.
The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors.
Hamblett CL, Methot JL, Mampreian DM, Sloman DL, Stanton MG, Kral AM, Fleming JC, Cruz JC, Chenard M, Ozerova N, Hitz AM, Wang H, Deshmukh SV, Nazef N, Harsch A, Hughes B, Dahlberg WK, Szewczak AA, Middleton RE, Mosley RT, Secrist JP, Miller TA. Hamblett CL, et al. Among authors: secrist jp. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5300-9. doi: 10.1016/j.bmcl.2007.08.023. Epub 2007 Aug 16. Bioorg Med Chem Lett. 2007. PMID: 17761416
29 results